Bibliographic Details
| Title: |
Dual-responsive renal injury cells targeting nanoparticles for vitamin E delivery to treat ischemia reperfusion-induced acute kidney injury. |
| Authors: |
Zhang, Jiahao1,2 (AUTHOR), Ren, Xi3,4 (AUTHOR), Nie, Zhaoyang4 (AUTHOR), You, Yue1,2 (AUTHOR), Zhu, Yao1 (AUTHOR), Chen, Hui1 (AUTHOR), Yu, Haichuan1 (AUTHOR), Mo, Gaozhi P.1 (AUTHOR), Su, Lianjiu1,2,5 (AUTHOR) sulianjiu@whu.edu.cn, Peng, Zhiyong1,2,6 (AUTHOR) pengzy5@hotmail.com, Tang, Man-Chung4 (AUTHOR) kobetang2021@sz.tsinghua.edu.cn |
| Source: |
Journal of Nanobiotechnology. 10/15/2024, Vol. 22 Issue 1, p1-18. 18p. |
| Subject Terms: |
*RETICULO-endothelial system, *ACUTE kidney failure, *CHRONIC kidney failure, *UNSATURATED fatty acids, *MATRIX metalloproteinases, *REPERFUSION, *VITAMIN E |
| Abstract: |
Ischemia/reperfusion (I/R) is an important inducer of acute kidney injury (AKI), and triggers the generation of reactive oxygen species (ROS) and the expression of matrix metalloproteinase 2 (MMP2), exacerbating kidney damage. Given the immense potential of vitamin E (VitE) as a natural fat-soluble antioxidant in kidney protection, we designed the nanoparticles (NPs) that could dual respond to ROS and MMP2, aiming to accurately deliver VitE to renal injury cells. The NPs utilized Gel-SH as a sensitive receptor for MMP2 and diselenide as a sensitive receptor for ROS, while PEG2k modification enhanced biocompatibility and prevented phagocytosis mediated by the mononuclear phagocyte system. The amphiphilic Gel-SH and diselenide encapsulate the liposoluble VitE and self-assemble into the NPs with a hydrodynamic size of 69.92 nm. Both in vivo and in vitro experiments based on these NPs show good biocompatibility and the ability of target renal injury cells. In vivo kidney I/R injury models and in vitro cell hypoxia/reoxygenation models, the NPs have demonstrated effects in reducing oxidative stress and alleviating AKI. Notably, VitE can preferentially react with peroxyl radical (LOO•) than polyunsaturated fatty acid (PUFA), inhibiting the formation of carbon centered radical (L•), thereby blocking the chain reaction between PUFA and LOO• in ferroptosis. The NPs also inhibit the transition from AKI to chronic kidney disease, with few side effects. Thus, the NPs with dual-responsiveness to MMP2 and ROS for targeted delivery of VitE to renal injury cells exhibit remarkable effects in inhibiting ROS and the chain reactions of ferroptosis, making it a promising therapeutic agent against AKI caused by I/R. [ABSTRACT FROM AUTHOR] |
|
Copyright of Journal of Nanobiotechnology is the property of BioMed Central and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Academic Search Complete |
|
Full text is not displayed to guests. |
Login for full access.
|
